Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair

J. Y. Park, T. R. Singh, N. Nassar, F. Zhang, M. Freund, H. Hanenberg, A. R. Meetei, P. R. Andreassen

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Heterozygous carriers of germ-line mutations in the BRCA2/FANCD1, PALB2/FANCN and RAD51C/FANCO DNA repair genes have an increased lifetime risk of developing breast, ovarian and other cancers; bi-allelic mutations in these genes clinically manifest as Fanconi anemia (FA). Here, we demonstrate that RAD51C is part of a novel protein complex that contains PALB2 and BRCA2. Further, the PALB2 WD40 domain can directly and independently bind RAD51C and BRCA2. To understand the role of these homologous recombination (HR) proteins in DNA repair, we functionally characterize effects of missense mutants of the PALB2 WD40 domain that have been reported in breast cancer patients. In contrast to large truncations of PALB2, which display a complete loss of interaction, the L939W, T1030I and L1143P missense mutants/variants of the PALB2 WD40 domain are associated with altered patterns of direct binding to the RAD51C, RAD51 and BRCA2 HR proteins in biochemical assays. Further, the T1030I missense mutant is unstable, whereas the L939W and L1143P proteins are stable but partially disrupt the PALB2-RAD51C-BRCA2 complex in cells. Functionally, the L939W and L1143P mutants display a decreased capacity for DNA double-strand break-induced HR and an increased cellular sensitivity to ionizing radiation. As further evidence for the functional importance of the HR complex, RAD51C mutants that are associated with cancer susceptibility and FA also display decreased complex formation with PALB2. Together, our results suggest that three different cancer susceptibility and FA proteins function in a DNA repair pathway based upon the PALB2 WD40 domain binding to RAD51C and BRCA2.

Original languageEnglish
Pages (from-to)4803-4812
Number of pages10
JournalOncogene
Volume33
Issue number40
DOIs
StatePublished - Oct 2 2014

Fingerprint

Homologous Recombination
DNA Repair
Breast Neoplasms
Fanconi Anemia
Fanconi Anemia Complementation Group Proteins
Proteins
Double-Stranded DNA Breaks
Germ-Line Mutation
Ionizing Radiation
Ovarian Neoplasms
Genes
Neoplasms
Breast
Mutation

Keywords

  • BRCA genes
  • BRCA2
  • DNA repair
  • Homologous recombination
  • PALB2
  • RAD51C

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics
  • Medicine(all)

Cite this

Park, J. Y., Singh, T. R., Nassar, N., Zhang, F., Freund, M., Hanenberg, H., ... Andreassen, P. R. (2014). Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair. Oncogene, 33(40), 4803-4812. https://doi.org/10.1038/onc.2013.421

Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair. / Park, J. Y.; Singh, T. R.; Nassar, N.; Zhang, F.; Freund, M.; Hanenberg, H.; Meetei, A. R.; Andreassen, P. R.

In: Oncogene, Vol. 33, No. 40, 02.10.2014, p. 4803-4812.

Research output: Contribution to journalArticle

Park, JY, Singh, TR, Nassar, N, Zhang, F, Freund, M, Hanenberg, H, Meetei, AR & Andreassen, PR 2014, 'Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair', Oncogene, vol. 33, no. 40, pp. 4803-4812. https://doi.org/10.1038/onc.2013.421
Park, J. Y. ; Singh, T. R. ; Nassar, N. ; Zhang, F. ; Freund, M. ; Hanenberg, H. ; Meetei, A. R. ; Andreassen, P. R. / Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair. In: Oncogene. 2014 ; Vol. 33, No. 40. pp. 4803-4812.
@article{5e3b6fce23dd4c04b308fcacbe729b6c,
title = "Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair",
abstract = "Heterozygous carriers of germ-line mutations in the BRCA2/FANCD1, PALB2/FANCN and RAD51C/FANCO DNA repair genes have an increased lifetime risk of developing breast, ovarian and other cancers; bi-allelic mutations in these genes clinically manifest as Fanconi anemia (FA). Here, we demonstrate that RAD51C is part of a novel protein complex that contains PALB2 and BRCA2. Further, the PALB2 WD40 domain can directly and independently bind RAD51C and BRCA2. To understand the role of these homologous recombination (HR) proteins in DNA repair, we functionally characterize effects of missense mutants of the PALB2 WD40 domain that have been reported in breast cancer patients. In contrast to large truncations of PALB2, which display a complete loss of interaction, the L939W, T1030I and L1143P missense mutants/variants of the PALB2 WD40 domain are associated with altered patterns of direct binding to the RAD51C, RAD51 and BRCA2 HR proteins in biochemical assays. Further, the T1030I missense mutant is unstable, whereas the L939W and L1143P proteins are stable but partially disrupt the PALB2-RAD51C-BRCA2 complex in cells. Functionally, the L939W and L1143P mutants display a decreased capacity for DNA double-strand break-induced HR and an increased cellular sensitivity to ionizing radiation. As further evidence for the functional importance of the HR complex, RAD51C mutants that are associated with cancer susceptibility and FA also display decreased complex formation with PALB2. Together, our results suggest that three different cancer susceptibility and FA proteins function in a DNA repair pathway based upon the PALB2 WD40 domain binding to RAD51C and BRCA2.",
keywords = "BRCA genes, BRCA2, DNA repair, Homologous recombination, PALB2, RAD51C",
author = "Park, {J. Y.} and Singh, {T. R.} and N. Nassar and F. Zhang and M. Freund and H. Hanenberg and Meetei, {A. R.} and Andreassen, {P. R.}",
year = "2014",
month = "10",
day = "2",
doi = "10.1038/onc.2013.421",
language = "English",
volume = "33",
pages = "4803--4812",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "40",

}

TY - JOUR

T1 - Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair

AU - Park, J. Y.

AU - Singh, T. R.

AU - Nassar, N.

AU - Zhang, F.

AU - Freund, M.

AU - Hanenberg, H.

AU - Meetei, A. R.

AU - Andreassen, P. R.

PY - 2014/10/2

Y1 - 2014/10/2

N2 - Heterozygous carriers of germ-line mutations in the BRCA2/FANCD1, PALB2/FANCN and RAD51C/FANCO DNA repair genes have an increased lifetime risk of developing breast, ovarian and other cancers; bi-allelic mutations in these genes clinically manifest as Fanconi anemia (FA). Here, we demonstrate that RAD51C is part of a novel protein complex that contains PALB2 and BRCA2. Further, the PALB2 WD40 domain can directly and independently bind RAD51C and BRCA2. To understand the role of these homologous recombination (HR) proteins in DNA repair, we functionally characterize effects of missense mutants of the PALB2 WD40 domain that have been reported in breast cancer patients. In contrast to large truncations of PALB2, which display a complete loss of interaction, the L939W, T1030I and L1143P missense mutants/variants of the PALB2 WD40 domain are associated with altered patterns of direct binding to the RAD51C, RAD51 and BRCA2 HR proteins in biochemical assays. Further, the T1030I missense mutant is unstable, whereas the L939W and L1143P proteins are stable but partially disrupt the PALB2-RAD51C-BRCA2 complex in cells. Functionally, the L939W and L1143P mutants display a decreased capacity for DNA double-strand break-induced HR and an increased cellular sensitivity to ionizing radiation. As further evidence for the functional importance of the HR complex, RAD51C mutants that are associated with cancer susceptibility and FA also display decreased complex formation with PALB2. Together, our results suggest that three different cancer susceptibility and FA proteins function in a DNA repair pathway based upon the PALB2 WD40 domain binding to RAD51C and BRCA2.

AB - Heterozygous carriers of germ-line mutations in the BRCA2/FANCD1, PALB2/FANCN and RAD51C/FANCO DNA repair genes have an increased lifetime risk of developing breast, ovarian and other cancers; bi-allelic mutations in these genes clinically manifest as Fanconi anemia (FA). Here, we demonstrate that RAD51C is part of a novel protein complex that contains PALB2 and BRCA2. Further, the PALB2 WD40 domain can directly and independently bind RAD51C and BRCA2. To understand the role of these homologous recombination (HR) proteins in DNA repair, we functionally characterize effects of missense mutants of the PALB2 WD40 domain that have been reported in breast cancer patients. In contrast to large truncations of PALB2, which display a complete loss of interaction, the L939W, T1030I and L1143P missense mutants/variants of the PALB2 WD40 domain are associated with altered patterns of direct binding to the RAD51C, RAD51 and BRCA2 HR proteins in biochemical assays. Further, the T1030I missense mutant is unstable, whereas the L939W and L1143P proteins are stable but partially disrupt the PALB2-RAD51C-BRCA2 complex in cells. Functionally, the L939W and L1143P mutants display a decreased capacity for DNA double-strand break-induced HR and an increased cellular sensitivity to ionizing radiation. As further evidence for the functional importance of the HR complex, RAD51C mutants that are associated with cancer susceptibility and FA also display decreased complex formation with PALB2. Together, our results suggest that three different cancer susceptibility and FA proteins function in a DNA repair pathway based upon the PALB2 WD40 domain binding to RAD51C and BRCA2.

KW - BRCA genes

KW - BRCA2

KW - DNA repair

KW - Homologous recombination

KW - PALB2

KW - RAD51C

UR - http://www.scopus.com/inward/record.url?scp=84916202537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916202537&partnerID=8YFLogxK

U2 - 10.1038/onc.2013.421

DO - 10.1038/onc.2013.421

M3 - Article

VL - 33

SP - 4803

EP - 4812

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 40

ER -